The Lancet Gastroenterology & Hepatology in conversation with

The Lancet Group
  • 0,0 (0)
  • GYÓGYÁSZAT
The Lancet Gastroenterology & Hepatology in conversation with

Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.

  1. NOV. 6.

    Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis

    Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00200-0?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljourna...

    15 perc

  2. NOV. 1.

    Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease

    Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.Read the full articles:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00264-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langashttps://www.thelancet.com/journals/langas/article/PIIS246...

    34 perc

  3. JÚL. 31.

    Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer

    Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/...

    18 perc

  4. JÚL. 1.

    Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy

    Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00084-0?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://...

    25 perc

  5. MÁJ. 17.

    Sanna Nybacka and Magnus Simrén on a trial of low FODMAP diets versus low carbohydrate diets in IBS

    Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00045-1/fulltext?dgcid=buzzsprout_tlv_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelan...

    23 perc

  6. MÁJ. 7.

    Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease

    Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/comp...

    20 perc

  7. ÁPR. 22.

    Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa

    Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00449-1?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://...

    21 perc

  8. MÁRC. 12.

    Mads Israelsen on validating the new steatotic liver disease nomenclature in people with excessive alcohol intake

    Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00443-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttp...

    17 perc
Összes (82)

Névjegy

Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.

Információ

Továbbiak tőle: The Lancet Group

Ezeket is kedvelheti

A szókimondó epizódok meghallgatásához jelentkezzen be.

Maradjon naprakész a műsorral kapcsolatban

Bejelentkezhet vagy regisztrálhat a műsorok követéséhez, az epizódok mentéséhez és az újdonságokról való értesüléshez.
Válasszon egy országot vagy régiót

Afrika, Közel-Kelet és India

Ázsiai csendes-óceáni régió

Európa

Latin-Amerika és Karib-térség

Egyesült Államok és Kanada